Petar Jelinic
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Chromatin Remodeling and Cancer, Cancer Immunotherapy and Biomarkers, Cancer Mechanisms and Therapy, Cancer Genomics and Diagnostics
Most-Cited Works
- → Recurrent SMARCA4 mutations in small cell carcinoma of the ovary(2014)373 cited
- → Loss of imprinting and cancer(2006)230 cited
- → Homologous Recombination Deficiency: Concepts, Definitions, and Assays(2022)211 cited
- → The Testis-Specific Factor CTCFL Cooperates with the Protein Methyltransferase PRMT7 in H19 Imprinting Control Region Methylation(2006)197 cited
- → Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade(2017)156 cited
- → CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary(2019)110 cited
- → Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type(2015)104 cited
- → A Novel Mammalian Complex Containing Sin3B Mitigates Histone Acetylation and RNA Polymerase II Progression within Transcribed Loci(2010)88 cited
- → New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair(2014)82 cited
- → Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type(2015)73 cited